An observational study in Diabete Mellitus and MASLD, sponsored by National University Health System, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by National University Health System, Singapore · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Diabetes Mellitus with a site in Singapore — 10 open to participants now, 15 under way, none of them phase 3. Diabetes Mellitus · Singapore.
Among the 89 studies in Diabetes Mellitus with a site in Singapore, this one is the 12th largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2026, is one of 16 observational ones, reaches primary completion later than 8 of the 14 other live ones, and was the 88th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →10 of the 89 studies in Diabetes Mellitus with a site in Singapore are open now. Recruiting first, the newest first:
National University Hospital, Singapore · Sites in Singapore
Ages 21–45 · Women only
Lynette Goh · Sites in Singapore
Ages 21–59
Duk-Woo Park, MD · Sites in Singapore, United States, Australia and 11 more countries
Ages 20+
National Healthcare Group Polyclinics · Sites in Singapore
Ages 21–64
Singapore General Hospital · Sites in Singapore
Ages 40–75
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 21 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 270 is close to the median of 246 across 1,935 observational studies indexed under Diabetes Mellitus.
Median enrollment 137 across the 73 interventional studies, 871 across the 16 observational. Of the 58 that completed or were terminated, 10 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 89 have an industry lead sponsor. The 10 most frequent:
National University Health System, Singapore is the lead sponsor of 42 studies on the registry; 12 are open to participants now.
National University Health System, Singapore has 4 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes Mellitus with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07861191National University Health System, SingaporeRESET-INSPIRE Study: Insulin Sensitivity & Population Intervention With Real-time Evaluation Using CGM | 2026-12-31 |
| NCT06484543Institute for Human Development and Potential (IHDP), SingaporeBrown Fat as Therapeutic Strategy for Obesity and Associated Metabolic Diseases Via Functional Food/Nutraceutical Approach - Molecular Mechanisms of Pentacyclic Triterpenes (BRACE) | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 89 studies in Diabetes Mellitus with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The RESET-INSPIRE study is designed to investigate individual variability in glucose response and insulin sensitivity, a key mechanism underlying metabolic-associated steatotic liver disease (MASLD) and cardiometabolic disorders. Building on findings from Project RESET, this study aims to develop and validate a continuous glucose monitoring (CGM)-based approach for assessing insulin sensitivity.
Insulin resistance is a key factor in the development of metabolic-associated steatotic liver disease (MASLD) and cardiovascular-metabolic disease (CVMD). It occurs when tissues such as skeletal muscle, fat, and liver respond poorly to insulin, leading to metabolic imbalance.
In skeletal muscle, insulin resistance reduces glucose uptake after meals, leaving blood sugar elevated for longer. This contributes to stress on pancreatic beta-cells and damages blood vessels and the heart. In adipose tissue, impaired insulin action increases the release of free fatty acids, which build up in the liver, muscle, and heart, worsening fat accumulation and mitochondrial dysfunction. In the liver, insulin resistance prevents proper suppression of glucose production, causing fasting hyperglycemia and accelerating progression to diabetes.
Together, these tissue-specific changes drive hyperglycemia, abnormal lipid levels, inflammation, and vascular dysfunction-hallmarks of metabolic syndrome. Early detection and targeted management of insulin resistance are therefore crucial for preventing MASLD and CVMD This study will enable evaluation of CGM-derived metrics against established OGTT-based measures, providing insights into early metabolic dysfunction in individuals without diabetes under both controlled and real-world conditions.
Recruitment is in Singapore as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
There is only one study cohort for Project Inspire, and no interventions are done on them as this is an Observational study.
Continuous Glucose Monitor data
The continuous Glucose Monitor measures glucose in the interstitial fluid under the skin and outputs it in units of mmol/L
Time frame: 15 days
Blood Glucose
Blood glucose is measured at all timepoints for the OGTT and is output in mmol/L
Time frame: 2 hours
Insulin
Insulin in the blood is measured at all timepoints of the OGTT and output in mU/L
Time frame: 2 hours
C-Peptide
C-Peptide levels in the blood is measured at all timepoints of the OGTT and output as ng/ml
Time frame: 2 hours
HBA1C
Blood HBA1C measured in the fasting blood sample during the OGTT and output in percentage (%)
Time frame: At the start of OGTT
hs-CRP
hs-CRP measured in the fasting blood sample and output as mg/L.
Time frame: At the start of the OGTT
ESR (Alifax)
Erythrocyte Sedimentation Rate (Blood) measures ESR (Alifax) and outputs in mm.hr
Time frame: At the start of OGTT
Total Cholesterol
Blood Total Cholesterol in the fasting blood sample output in mmol/L
Time frame: At the start of OGTT.
HDL Cholesterol
HDL Cholesterol measured in the fasting blood sample and output in mmol/L
Time frame: At the start of OGTT
LDL Cholesterol
LDL cholesterol measured in the fasting blood sample and output in mmol/L
Time frame: At the start of OGTT
Triglycerides
Triglycerides measured in the fasting blood sample and output as mmol/L
Time frame: At the start of OGTT
Cholesterol/HDL Ratio
Ratio of fasting blood Cholesterol value and HDL cholesterol value output as a unitless number.
Time frame: At the start of OGTT
Total Protein
Total Protein measured in Fasting Blood Sample and output as g/L
Time frame: At the start of OGTT
Albumin
Albumin measured in the Fasting Blood Sample and output as g/L
Time frame: At the start of OGTT
Globulin
Globulin measured in the Fasting Blood Sample and output as g/L
Time frame: At the start of OGTT
A/G ratio
Ratio of Albumin and Globulin measured in the Fasting Blood Sample, unitless output.
Time frame: At the start of OGTT
Bilirubin, total
Bilirubin, total measured in the Fasting Blood Sample and output as umol/L
Time frame: At the start of OGTT
Bilirubin, direct
Bilirubin, direct measured in the Fasting Blood Sample and output as umol/L
Time frame: At the start of OGTT
Bilirubin, indirect
Bilirubin, indirect measured in the Fasting Blood Sample and output as umol/L
Time frame: At the start of OGTT
Alkaline Phosphatase
Alkaline Phosphatase measured in Fasting Blood Sample and output as U/L
Time frame: At the start of OGTT
SGPT/ALT
Serum Glutamic Pyruvic Transaminase / Alanine Aminotransferase measured in Fasting Blood Sample and output as U/L
Time frame: At the start of OGTT
SGOT/AST
Serum glutamic-oxaloacetic transaminase/Aspartate aminotransferase measured in Fasting Blood Sample and output in U/L
Time frame: At the start of OGTT
Gamma GT
Gamma-glutamyl transferase measured in Fasting Blood Sample and output in U/L
Time frame: At the start of OGTT
Phosphate
Phosphate measured in the Fasting Blood Sample and output as mmol/L
Time frame: At the start of OGTT
Calcium
Calcium measured in the Fasting Blood Sample and output as mmol/L
Time frame: At the start of OGTT
Uric Acid
Uric Acid measured in the Fasting Blood Sample and output as mmol/L
Time frame: At the start of OGTT
Rheumatoid Factor
Rheumatoid Factor measured in the Fasting Blood Sample and output as IU/ml
Time frame: At the start of OGTT
Sodium
Sodium measured in Fasting Blood Sample and output as mmol/L
Time frame: At the start of OGTT
Potassium
Potassium measured in the Fasting Blood Sample and output as mmol/L
Time frame: At the start of OGTT
Chloride
Chloride measured in Fasting Blood Sample and output in mmol/L
Time frame: At start of OGTT
Urea
Urea measured in Fasting Blood Sample and output as mmol/L
Time frame: At start of OGTT
Creatinine
Creatinine measured in Fasting Blood Sample and output as umol/L
Time frame: At start of OGTT
eGFR
eGFR measured in Fasting Blood Sample and output as ml/min/1.73m\^2
Time frame: At Start of OGTT
Free T4
Free T4 measured in the Fasting Blood Sample and output as pmol/L.
Time frame: At the start of OGTT
TSH
TSH measured in Fasting Blood Sample and output as mIU/L
Time frame: At the start of OGTT
Haemoglobin
Haemoglobin measured in Fasting Blood sample and output as g/dL
Time frame: At the start of the OGTT
Red cell count
Red cell count measured in the Fasting Blood Sample and output as x10\^12/L
Time frame: At the start of the OGTT
Total White cell count
Total White cell count measured in the Fasting Blood Sample and output as x10\^9/L.
Time frame: At the start of the OGTT
Neutrophils
Neutrophils measured in the Fasting Blood Samples and output as both % and x10\^9/L.
Time frame: At the start of the OGTT
Lymphocytes
Lymphocytes measured in the Fasting Blood Sample and output as both % and x10\^9/L
Time frame: At the start of the OGTT
Monocytes
Monocytes measured in the Fasting Blood Sample and output as both % and x10\^9/L
Time frame: At the start of the OGTT
Eosinophils
Eosinophils measured in the Fasting Blood Samples and output as both % and x10\^9/L
Time frame: At the start of the OGTT
Basophils
Basophils measured in the Fasting Blood Sample and output in both % and x10\^9/L
Time frame: At the start of the OGTT
Haematocrit (PCV)
Haematocrit (PCV) measured in Fasting Blood Sample and output in a unitless format.
Time frame: At the start of the OGTT
MCV
MCV measured in the Fasting Blood Sample and output as fL.
Time frame: At the start of the OGTT
MCH
MCH measured in the Fasting Blood Sample and output as pg.
Time frame: At the start of the OGTT
MCHC
MCHC measured in the fasting blood sample and output as g/dL
Time frame: At the start of the OGTT
RDW
RDW measured in the Fasting Blood Sample and output as %
Time frame: At the start of the OGTT
Platelets
Platelets measured in the Fasting Blood Sample and output in x10\^9/L
Time frame: At the start of the OGTT
Peripheral Blood Film
Peripheral Blood Film analyzed from the Fasting Blood Sample and described verbally.
Time frame: At the Start of the OGTT.
NT-ProBNP
NT-ProBNP measured from the Fasting Blood Sample and output in pg/ml
Time frame: At the start of the OGTT
hs Troponin-I
hs Troponin-I measured in the Fasting Blood Sample and output in pg/ml
Time frame: At the start of the OGTT
Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.
Of 534 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 159. This study's planned 5 months is below that.
Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National University Health System, Singapore